Pancreatic Cancer Research

ResearcherThe University of TokyoNo recent work listed

Tomotaka Saito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6008-1648; OpenAlex author ID A5048880794. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 10

  1. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  2. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  3. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  4. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  5. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  6. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  7. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  8. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  9. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  10. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 10 shared papers, 2014–2023 · strength 0.79
  2. Naminatsu Takahara · 9 shared papers, 2015–2023 · strength 0.76
  3. Kei Saito · 9 shared papers, 2015–2023 · strength 0.76
  4. Tsuyoshi Hamada · 9 shared papers, 2014–2023 · strength 0.72
  5. Kazunaga Ishigaki · 8 shared papers, 2015–2023 · strength 0.70
  6. Suguru Mizuno · 9 shared papers, 2014–2021 · strength 0.63
  7. Hirofumi Kogure · 9 shared papers, 2014–2021 · strength 0.63
  8. Kazuhiko Koike · 9 shared papers, 2014–2021 · strength 0.63
  9. Hiroyuki Isayama · 8 shared papers, 2014–2021 · strength 0.53
  10. Yukari Suzuki · 3 shared papers, 2020–2023 · strength 0.35
  11. Minoru Tada · 6 shared papers, 2014–2019 · strength 0.32
  12. Hideaki Ijichi · 5 shared papers, 2014–2021 · strength 0.32
  13. Hiroki Oyama · 2 shared papers, 2020–2023 · strength 0.25
  14. Tsuyoshi Takeda · 4 shared papers, 2015–2019 · strength 0.24
  15. Saburo Matsubara · 4 shared papers, 2015–2019 · strength 0.22
  16. Tatsunori Suzuki · 1 shared paper, 2023 · strength 0.16
  17. Mitsuhiro Fujishiro · 1 shared paper, 2023 · strength 0.16
  18. Yasuyuki Seto · 1 shared paper, 2021 · strength 0.11
  19. Takahiro Kishikawa · 2 shared papers, 2015–2019 · strength 0.11
  20. Takashi Sasaki · 1 shared paper, 2019 · strength 0.07
  21. Takashi Sasaki · 2 shared papers, 2014–2015 · strength 0.07
  22. Koji Miyabayashi · 2 shared papers, 2014–2015 · strength 0.07
  23. Naoki Sasahira · 2 shared papers, 2014–2015 · strength 0.07
  24. Dai Mohri · 1 shared paper, 2015 · strength 0.03
  25. Keisuke Yamamoto · 1 shared paper, 2015 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.